Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
如果獲得批准,Acumen Pharmicals與Lonza合作,涵蓋用於阿爾茨海默氏病的Sabirnetug(ACU193)的製造,用於臨床開發和商業化